Sevuparin

Novel, proprietary treatement for Sickle Cell Disease currently in clinical phase II.

Learn more

Sickle Cell Disease

An orphan disease with large unmet medical need.

Learn more

Modus Therapeutics completes a SEK 140m financing led by HealthCap

Sevuparin receives Rare Pediatric Disease Designation from FDA for the treatment of children with sickle cell disease

Learn more about our ongoing Phase 2 Study

Recruiting at hospitals in the Netherlands, Jamaica, Turkey, Lebanon, Saudi Arabia, Bahrain and Oman.

Modus Therapeutics granted two European Patents

The European Patent Office has granted Modus Therapeutics two European patents.

Dr. John Öhd appointed Chief Medical Officer at Modus Therapeutics

Dr. Öhd joins Modus from Medivir AB, where he was CMO and a member of the company’s Executive Management team

Marketwatch interview with Modus's CEO Ellen Donnelly

The privately held Swedish biotech Modus Therapeutics is running clinical trials for its sickle cell drug, sevuparin, in the Middle East, where sickle cell disease is prevalent